UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
February 12, 2008
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
001-32335
|
|
88-0488686 |
| |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
|
|
| 11388 Sorrento Valley Road, San Diego, California |
|
92121 |
| |
|
|
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 794-8889
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Item 7.01 Regulation FD Disclosure.
Attached hereto as Exhibit 99.1, which is incorporated herein by reference, is a copy of
certain slides used by Halozyme Therapeutics, Inc., in making an investor presentation and that are
expected to be used in subsequent presentations to interested parties, including analysts and
stockholders.
This information is being furnished pursuant to Item 7.01 of this Report and shall not be
deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that section and will not be incorporated by
reference into any registration statement filed by Halozyme Therapeutics, Inc., under the
Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by
reference. This Report will not be deemed an admission as to the materiality of any information in
this Report that is being disclosed pursuant to Regulation FD.
Please refer to page 2 of Exhibit 99.1 for a discussion of certain forward-looking statements
included therein and the risks and uncertainties related thereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
|
|
|
99.1
|
|
Halozyme Therapeutics, Inc., Investor Presentation dated February 12, 2008. |